Report of a Meeting

Second Partners Meeting on Better Medicines for Children

WHO Headquarters, Geneva, Switzerland
14-15 October 2010

This publication contains the report of the Second Partners Meeting on Better Medicines for Children and does not necessarily represent the decisions or policies of the World Health Organization.
# Table of contents

Executive summary.................................................................................................................3  
Introduction .............................................................................................................................4  
Progress made..........................................................................................................................5  
WHO .....................................................................................................................................5  
Countries ................................................................................................................................6  
Ghana .....................................................................................................................................6  
The United Republic of Tanzania.......................................................................................7  
India........................................................................................................................................7  
Global initiatives ....................................................................................................................7  
Ongoing work..........................................................................................................................8  
WHO .....................................................................................................................................8  
Global initiatives ....................................................................................................................9  
Action areas identified ..........................................................................................................11  
Research and development .................................................................................................11  
Policy, regulation, procurement and supply in countries ....................................................12  
Advocacy and communications ............................................................................................12  
Funding ..................................................................................................................................13  
Partnerships ...........................................................................................................................13  
Emerging and other issues ....................................................................................................13  
Working groups ....................................................................................................................14  
TB medicines for children ....................................................................................................14  
Weight measurement ............................................................................................................14  
Human resources capacity .....................................................................................................14  
Agenda .................................................................................................................................15  
List of participants ..................................................................................................................17
Executive summary

The Better Medicines for Children project aims to promote better use of medicines in children, promote access to medicines for children, fill knowledge gaps about priority medicines for children and promote research and development of essential medicines for children. The project is funded by the Bill and Melinda Gates Foundation and is in the second year.

A partners meeting was held to share information on progress related to the Better Medicines for Children project; to provide a forum for exchange of ideas; to foster commitment to a continued partnership; and to identify the way forward to complete the objectives set out in resolution WHA60.20 on Better Medicines for Children. The meeting was attended by WHO staff from the Medicines, Access and Rational Use team, members of the implementation teams from Ghana, India and the United Republic of Tanzania, and experts, researchers and representatives from organizations having an interest in Better Medicines for Children.

Progress has been made by WHO on a number of areas such as paediatric tuberculosis, with the finalization and publication of a number of studies on medicines and updated guidelines for the treatment of tuberculosis in children. In addition, the WHO Model Formulary for Children has been published, workshops on Essential Medicines Lists have been held and the Pediatric medicines Regulatory Network has been established.

Three countries, Ghana, India and the United Republic of Tanzania have been implementing the objectives to promote access to and use of better medicines for children. Progress has been made in Ghana and India, in completing baseline surveys and the United Republic of Tanzania is preparing for the assessment. A number of global initiatives are under way that contribute to promoting better use of medicines in children, promoting access to medicines for children, filling knowledge gaps about priority medicines for children and promoting research and development of essential medicines for children.

Work is still needed on a number of topics in order to develop effective interventions to improve the use of medicines in children. Action is required on research and development for appropriate dosing and formulations; guidance on clinical trials in children and suitable regulatory pathways to ensure the availability of better medicines for children. Country level training and guidance for procurement and supply chain management, for regulatory procedures, and for the policy adoption process is needed to improve availability of medicines in countries. Funding, advocacy and partnerships with key stakeholders is needed to carry this work forward.
Working groups were set up to consider the following areas: the need for appropriate dosages and formulations for the treatment of tuberculosis in children; the lack of knowledge on human resource capacity for medicines for children; and the need for appropriate weight estimation tools for dosing decisions.

**Introduction**

**Overview**

The World Health Assembly resolution WHA60.20 approved in May 2007, called for action for better medicines for children. The World Health Organization, Department of Essential Medicines and Pharmaceutical Policies obtained a grant from the Bill and Melinda Gates Foundation for the Better Medicines for Children project. This project includes work on: promoting better use of medicines in children, promoting access to medicines for children in priority countries, filling knowledge gaps for priority medicines for children and promoting research and development of essential medicines for children by providing clinical evidence, guidance and specifications for missing products.

This report outlines the highlights of the Second Partners Meeting on Better Medicines for Children and the discussion on the way forward. Presentations are available upon request.

**Meeting objectives**

**To share information on progress related to the Better Medicines for Children project.**

The Second Partners Meeting on Better Medicines for children took place 18 months after the first partners meeting and 2 years into the Bill and Melinda Gates-funded project. Considerable progress has been made in that time by WHO, in countries and through a number of global initiatives.

**To provide a forum for an exchange of ideas.**

The meeting was attended by WHO staff from the Medicines, Access and Rational Use team at WHO Geneva, members of the implementation teams from Ghana, India and the United Republic of Tanzania, and experts, researchers and representatives from organizations with a stake in Better Medicines for Children.

**To foster commitment to a continued partnership.**

With 18 month remaining on the Gates project and much work still to be done, the partners meeting aimed to encourage partners to work together to craft strategies to meet challenges and overcome constraints and to sustain their commitment to Better Medicines for Children.
To identify the way forward to complete the objectives set out in resolution WHA60.20 on Better Medicines for Children.¹

Despite the progress that has been made there is still much work to do to improve access to better medicines for children and to achieve health outcomes and reduce morbidity and mortality in children.

**Progress made**

**WHO**

WHO works towards the development of norms and standards including: harmonization of clinical trials, Essential Medicines Lists for children (EMLc) and clinical guidelines. WHO also promotes norms and standards for the quality and safety of children’s medicines and works to increase in regulatory capacity. Another important component of work includes making treatment guidelines and information on medicines available. WHO also encourages adequate financing for medicines for children.

During the last year there has been progress on:

- **Medicines for paediatric tuberculosis:**
  - Comprehensive review of clinical evidence and safety of tuberculosis medicines for children.²
  - Pharmacokinetic simulations to suggest a fixed-dose combination formulation for pediatric tuberculosis.³
  - A review of fluoroquinolone use in paediatric patients.⁴
  - Feasibility study on fixed-dose combinations for tuberculosis treatment which showed that there are challenges in the production of an appropriate fixed-dosage form for children.
  - Updated guidelines for the treatment of tuberculosis in children.⁵

---

¹ [www.who.int/childmedicines/publications/en/](http://www.who.int/childmedicines/publications/en/)
² [www.who.int/childmedicines](http://www.who.int/childmedicines)
³ [www.who.int/selection_medicines/committees/expert/17/application/TB_Children.pdf](http://www.who.int/selection_medicines/committees/expert/17/application/TB_Children.pdf)
⁴ [www.who.int/childmedicines](http://www.who.int/childmedicines)
• Publication of the WHO Model Formulary for Children.¹
  o The first edition of the WHO Model Formulary for children has been prepared, based on the 2nd edition of the Essential Medicine List for children, to provide information about use, dosage, adverse effects, and contraindications for the medicines on the EMLc.

• Publication of the joint UNICEF/WHO Second edition of Sources and Prices of Selected Medicines for Children.²
  o This edition offers up-to-date information on the availability and price of different paediatric formulations selected from the EMLc.

• Inter-country workshops on Essential Medicines Lists (EML), held in English³ and French:⁴
  o Countries shared information on national EMLs and related activities. Potential activities in relation to the development of national EMLc were reviewed.

• Recommendations for the preferred dosage forms of medicines for children adopted by the Expert Committee on the Selection and Use of Essential Medicines; for flexible solid, oral formulations that can be administered at the point of care.

Countries

Work has started in three countries, Ghana, India and the United Republic of Tanzania on implementing strategies to improve access to and use of medicines for children.

Ghana

The BMC project was launched in Ghana in April 2010. Since the start of the project a baseline survey/literature review of existing information about medicines for children, an assessment of local manufacturing capacity and pricing and availability studies have been completed. In addition, a Drugs and Therapeutic Committee (DTC) peer review workshop for the Southern Sector of Ghana has been held and an assessment of the quality of paediatric care has been carried out. The data will form part of the requisite baseline for implementation work in 2011.

¹ www.who.int/selection_medicines/list/WMFc_2010.pdf
² www.who.int/medicines/publications/essentialmedicines/Sources_Prices2010.pdf
³ www.who.int/childmedicines/progress/Accra_final.pdf
⁴ www.who.int/childmedicines/progress/Ghana_French.pdf
The United Republic of Tanzania

Work has commenced with the establishment of a Better Medicines for Children technical working group, the development of DTC guidelines and Standard Treatment Guidelines for children based on the Pocketbook of Hospital Care for Children. Although a work plan was approved in April 2010, the Better Medicines for Children project was delayed due to organizational changes in the Ministry of Health that affected the timing of all funded activities.

India

The Better Medicines for Children project in India aims to improve the availability of essential medicines for children by developing and implementing an Essential Medicines List for children in two states, Orissa and Chhattisgarh. Pricing and availability studies in the two states are planned pre- and post-intervention. Training for the data collection has already been completed. Essential Medicines Lists for children are being developed in the two states as well as by the Indian Academy of Paediatrics at a national level.

Global initiatives

A number of global initiatives are under way which contribute to Better Medicines for Children. Progress on the following initiatives was shared:

- A study was carried out by the Institute for Pediatric Innovation and Dartmouth on practices and end-use preference for medicines for children in Tanzania. More than six hundred health care workers, caregivers and children were surveyed. Preliminary key results show that:
  - Crushed pills mixed with water are the most common method of administration in newborn babies and children under 6. Breaking and swallowing pill fractions was also common. This raises issues of accuracy of dosing, palatability of the mixture and adherence.
  - An overwhelming preference for sweet liquids or suspensions was expressed by children, parents and healthcare workers.
  - There was a lack of familiarity with dispersible medicines among all groups surveyed.

- A study was carried out by the Ecumenical Pharmaceutical Network in church health facilities in Kenya to determine the level of availability and the pricing of children’s medicines and to investigate the factors impacting access. Notable findings were:
Responsibility for medicine selection was mostly in the hands of the heads of facilities.

Lack of adequate financing was the main factor hampering the procurement of medicines for children.

- A review of the decision-making process for policies relating to children’s products was carried out by Medicines for Malaria Venture. Key findings showed:
  - That all stakeholders (policy makers, clinicians, procurement managers, donors) need to be informed about options for new products and involved in disseminating the necessary information to facilitate its uptake and correct use.
  - There is a need for efficacy and resistance data for medicines currently in use and also for alternative medicines.
  - Financial resources for purchasing the alternative medicines should be in place.
  - An agreed process for policy change needs to be established.

### Ongoing work

#### WHO

- WHO and UNICEF held a meeting of stakeholders in September 2010 to agree on a core list of the top 20 priority essential medicines for child survival. The list will be launched together with a list of priority medicines for maternal care. The aim is to provide a core list of medicines that must be available to procurement authorities.

- A new objective for the Better Medicines for Children project has been approved, that aims to develop and implement a communications strategy targeting manufacturers in India and key supply chain stakeholders in Ghana and Tanzania to promote the manufacture, procurement and supply of essential paediatric medicines.

- Guidelines for treatment of chronic pain in children are in the final review stages: they will be submitted for approval to the WHO Guidelines Review Committee in November and are planned for publication in the first quarter of 2011.

- The Paediatric medicines Regulatory Network (PmRN) was established as a forum for discussion and to raise awareness on paediatric medicines’ regulatory issues. Work to expand the network is progressing and will be discussed further.

- Now that the Model Formulary for Children has been published, plans to actively implement it are being developed.

---

• An updated version of the Pocketbook of Hospital Care for Children is in preparation with a target for publication in June 2011.

• There will be a workshop on paediatric medicines at the ICDRA meeting in Singapore, 30 Nov - 3 December 2010.

**Global initiatives**

Information on the following initiatives was shared at the meeting:

• A database has been made public by the European Medicines Agency that lists all clinical trials. Plans to include information on clinical trials in children in an updated version are under way. However, publication of the updated version has been delayed due to the unexpected amount of information that has been identified and received by the Agency for assessment.

• The European Medicines Agency is working on guidance for clinical trials in children with regard to design, assessment and assessment of results.

• The Highly active antiretroviral treatment (HAART) for Children Campaign has been launched by Caritas Internationalis and the Ecumenical Advocacy Alliance in 2009 to communicate to governments and pharmaceutical companies that priority should be given to the needs of children living with HIV and HIV-TB co-infection. A practical advocacy initiative proposed by the HAART Campaign is a children letter writing action – Prescriptions for life – which encourages young people to write letters to the Ministries of Health of their respective countries and to pharmaceutical company executives to request that these key decision-makers promote additional research and product development within the context of promoting the access better medicine for children living with HIV.

• The Clinton Health Access Initiative (CHAI) is engaged in fostering a ‘healthy’ market for children’s medicines, that will give suppliers to access information about demand, and thus allowing them to plan their research and development activities, and also their production schedules. It will also allow governments and purchasers to know about product availability and to negotiate prices.

• UNICEF has been working on many aspects of market shaping and supply management for children’s products, including demand management, advocacy, information and communication, and resource mobilization.
  o UNICEF carried out a gap analysis of products required for community case management of pneumonia, malaria and diarrhea based on country and global IMCI guidelines that are used in selected countries in Africa.

---

1 www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000044.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac05800260a3
This revealed that, in some instances, there are no suitable products to meet the guideline needs, while in other instances, the guidelines requested too many variants of the same product, potentially fragmenting the market.

- UNICEF has published a paper on dispersible tablets to support decision making at country level.¹
- Collaborations to investigate the possibility to provide ‘minimum requirements/technical specifications’ for taste masking and taste screening for medicines for children’, have shown that more work is required to determine optimal formulations.

- MSF is encouraging better formulations of HIV, TB and malaria medicines, needed for their operations. Field activities include antibiotic resistance surveys, adherence studies (such as use of co-blister-fixed dose combinations for artesunate/amodiaquine in Sierra Leone), lobbying for rectal artesunate and replacement of quinine with artemunate/arthemether.
- The UK Medicines for Children Research Network is providing infrastructure to support studies which address safety and efficacy of medicines in children. It also provides a coordination point for clinical research and works to ensure that research addresses priority needs of children.
- A project to find the best method to estimate body weight easily and reliably in children from infancy to 16 years has been developed and tested by Children’s Mercy Hospitals and Clinics. Further validation of this method in low-resource settings is urgently needed so that the children’s products that are now becoming available can be administered correctly to individual patients.
- The National Institute for Health has established a Pediatric Terminology Initiative to address the lack of consistent child health terminology with respect to clinical trials in children.
- Ways to bring people together through the International Pediatric Association and
- The International Union of Basic and Clinical Pharmacology, Division Of Clinical Pharmacology were discussed.
- The Global Research in Paediatrics initiative funded the EU 7th Framework Program aims to stimulate and facilitate the development and safe use of medicines in children and endorse a common approach to paediatric needs; to complement research efforts and reduce fragmentations; and to facilitate paediatric medicine innovation. A key element will be development of a global Paediatric Clinical Pharmacology Training Program.

¹ http://www.unicef.org/supply/index_53571.html UNICEF
• The International Federation of Pharmaceutical Manufacturers (IFPMA) Paediatric Task Force will continue a survey of paediatric clinical trials and will participate in the development of global standards. In addition, the IFPMA plans to develop a position paper on flexible solid oral dosage forms as the formulation of choice and will continue to collaborate with the Paediatric medicines Regulatory Network.

• The International Development Research Centre is currently carrying out a pilot project in Uganda to evaluate SMS text messaging to improve integrated community case management of acute respiratory infections, pneumonia, malaria and diarrhea in children.

• There is an increasing number of projects using cell phone technology. Some that were discussed at the meeting included:
  - A UNICEF project which uses cell phone technology for supply chain management in northern Uganda
  - The SMS for Life project in Tanzania that addresses needs in supply chain management.

<table>
<thead>
<tr>
<th>Upcoming meetings</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>14th International Conference of Drug Regulatory Authorities</td>
<td>Singapore</td>
<td>30 Nov - 3 Dec 2010</td>
</tr>
<tr>
<td>Health Africa Summit</td>
<td>Accra, Ghana</td>
<td>2-3 Dec 2010</td>
</tr>
<tr>
<td>The International Pharmaceutical Excipients Council Europe, Annual Seminar</td>
<td>Cannes, France</td>
<td>27 Jan 2011</td>
</tr>
<tr>
<td>Expert Committee on the Selection and Use of Essential Medicines</td>
<td>Accra, Ghana</td>
<td>March 2011</td>
</tr>
<tr>
<td>Third International Conference on Improving Use of Medicines</td>
<td>Alexandria, Egypt,</td>
<td>10-14 April 2011</td>
</tr>
<tr>
<td>World Congress of Pharmacy and Pharmaceutical Sciences 2011</td>
<td>Hyderabad, India</td>
<td>2 - 8 Sept 2011</td>
</tr>
</tbody>
</table>

**Action areas identified**

Areas for action that were discussed at the meeting were as follows:

**Research and development**

• Research and development is needed for the development of appropriate children’s medicines for HIV/AIDS, palliative care, neonatal care and non communicable diseases such as cardiovascular disease and epilepsy.
• Research and development will also be required to identify appropriate formulations that are flexible solid oral dosage forms, appropriate for use by children, adapted to low-resource settings and practical for the supply chain.

• Studies on shapes and sizes of tablets that can be swallowed by children should be carried out.

• Tuberculosis treatment in children is an area which requires urgent development of a fixed-dose combination. A working group has been established to propose an action plan to address this need (see next section).

• Regulatory pathways need to be defined, for new formulations of well known medicines standards.

Policy, regulation, procurement and supply in countries

• Understanding what is happening in countries with respect to supply chains, policy making and reality is required in order to understand the challenges.

• Additional support is needed to map the supply chain to community level.

• Training and guidance for procurement and supply chain management, regulatory guidance, clinical trial skills and policy adoption process at country level is essential.

• Understanding country use of Essential Medicines Lists will help to determine their role in procurement and supply and to develop the best strategies for dissemination and implementation. Too often, Essential Medicines Lists sit on the shelf and are not used.

• Guidance is needed to support Ministries of Health on priority setting when preparing procurement lists against limited budgets.

• A working group has been established to propose an action plan to address support for National Medicines Regulatory Agencies (See next section).

Advocacy and communications

• Broader communications are called for, particularly with regard to communicating successfully to effect change. Strategies need to be developed which address both supply and demand.

• Advocacy is needed to ensure that national procurement lists have specific sections for medicines for children.

• Continued advocacy will be required to ensure that appropriate financing of medicines for children is obtained.

• Acceptance and use of new dosage forms will require effective advocacy and communications.
Funding

Funding to support the Better Medicines for Children project will be required to carry the work forward in many of the above mentioned areas. In particular areas that require funding include:

- Research and development for medicines that have smaller markets.
- Procurement of medicines for children.
- A technology-based platform to integrate information on EMLc, the WHO Model Formulary for children, supply and procurement, extemporaneous preparations (Global virtual Warehouse), procurement and supply management and all guidance documents on medicines for children.

Partnerships

- Finding commercial partners willing to develop paediatric medicines and to produce for smaller markets is essential.
- Local manufacturing capacity needs to be assessed taking into account the market scales that are needed to justify investments.
- Thought should be given to procurement interventions such as pooled procurement and registration mechanisms that simplify regulatory procedures.
- It will be important to continue to work with manufacturers that are willing and able to reach prequalification of their products.

Emerging and other issues

- How to harness mobile phone technology to improve access to better medicines for children should be explored further. One challenge, will be how to organize the many different types of hardware, software, add-ons and applications into interoperable systems. Dissemination of standard treatment guidelines using cell phone technology will be a first step.
- Packaging and labeling should be suitable for and understandable by health workers and caregivers in communities and sub-district health facilities, as well as in higher levels of health services. Research and consultation will be necessary to successfully design usable labeling on how to administer medicines in a wide variety of situations and by people with little or no education.
- There is a need to find the best method to estimate body weight easily and reliably for correct dosing for paediatric medications. A working group has been established to propose an action plan to address this need (see next section).
• The extent of **human resource capacity** in the area of children’s medicines is not well known. It was decided to create a stakeholder map to identify what resources are available. (See next section.)

• Investigation is required to determine if dispersible tablets can be safely dispersed in **breast milk**. Messaging on use of medicines in the context of Exclusive Breast Feeding should be considered.

### Working groups

Working groups were formed to address several priority areas which were discussed during the meeting. The working groups met to discuss initial ideas for proposals and then presented this to the meeting participants for further discussion. Following the meeting the working groups will develop the proposals further.

### TB medicines for children

The working group met to discuss the need for a new fixed-dose combination for tuberculosis product for use in children, containing an appropriate amount of active pharmaceutical ingredients. The group agreed that innovation in the formulation was required and that it would be important to meet and engage with manufacturers (including those generic manufacturers with advanced formulation capacity) and other stakeholders on this issue. In addition, funding would be necessary in the long term. A proposal will be developed further which will outline the plan for getting a quality assured product to market quickly and for developing flexible solid oral dosage forms of the optimal fixed dose combination products for the treatment of tuberculosis in children.

### Weight measurement

Following the presentation on the Mercy T.A.P.E. method of weight estimation in children, the working group discussed the feasibility of validating the method in low-resource settings and concluded that 1 to 2 full time personnel over a 3 month period would be needed to complete the validation. The protocol could be ready within the next 6 months. The implementation phase would then need to be discussed.

### Human resources capacity

There is a lack of trained personnel available worldwide to address key needs for better medicines for children and the lack of authoritative data on human resources is a complicating factor. The compilation of an asset map is proposed as a priority with a target date for distribution of a comprehensive report by December 31, 2011. It can be estimated that such an asset map could be compiled by one full time research assistant dedicated to the project for 12 months. An estimated total budget of US$100,000 would be required.
## Agenda

### Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 09.30</td>
<td>Introduction and welcoming remarks</td>
<td>Dr Clive Ondari Coordinator, MAR</td>
</tr>
<tr>
<td>09.30 - 10.00</td>
<td>Objectives of the meeting and WHO &quot;make medicines child size&quot; initiative - update on progress</td>
<td>Dr Suzanne Hill, MAR</td>
</tr>
<tr>
<td>10.00 - 10.20</td>
<td>Questions &amp; discussion</td>
<td></td>
</tr>
<tr>
<td>10.20 - 10.40</td>
<td>Coffee</td>
<td></td>
</tr>
</tbody>
</table>

### Promoting Better Use of Medicines in Children

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.40 - 11.00</td>
<td>Overview of activities, results and challenges</td>
<td>Ghana BMC project</td>
</tr>
<tr>
<td>11.00 - 11.20</td>
<td>Overview of activities, results and challenges</td>
<td>Tanzania BMC project</td>
</tr>
<tr>
<td>11.20 - 11.40</td>
<td>Overview of activities, results and challenges</td>
<td>India BMC project</td>
</tr>
<tr>
<td>11.40 - 12.00</td>
<td>Some results from the Ecumenical Pharmaceutical Network (EPN) &quot;children's medicine project&quot; study report June 2010 and further planning</td>
<td>Mr Albert Peterson (Ecumenical Pharmaceutical Network)</td>
</tr>
<tr>
<td>12.00 - 12.15</td>
<td>Cell phone project in western Uganda</td>
<td>Dr Stuart MacLeod (Child &amp; Family Research Institute)</td>
</tr>
<tr>
<td>12.15 - 13.00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>13.00 - 14.00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

### Promote Access to Medicines for Children in Priority Countries

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 14.20</td>
<td>Promoting the child’s right to health: Caritas Highly Active Anti-Retroviral Therapy (HAART) for children campaign (Campaign for greater access to paediatric HIV and TB testing and Treatment) and the Ecumencial Advocacy Alliance (EAA) actions on paediatric AIDS</td>
<td>Ms Francesca Merico (Caritas Internationalis)</td>
</tr>
<tr>
<td>14.20 - 14.40</td>
<td>CHAI's work related to paediatric ARVs</td>
<td>Ms Joanna Sickler (The Clinton Health Access Initiative (CHAI))</td>
</tr>
<tr>
<td>14.40 - 15.00</td>
<td>UNICEF</td>
<td>Ms Atieno Ojoo (Technical Specialist, Pharmaceuticals, Supply Division)</td>
</tr>
<tr>
<td>15.00 - 15.20</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>15.20 - 15.40</td>
<td>To discuss Netherlands Medicines &amp; Development Partnership (NMDP) objectives: advocate for public health based interventions across the entire spectrum of pharmaceutical policy - from medicine inception through R&amp;D, supply chain and access issues and the rational use and misuse of medicines</td>
<td>Ms Annelies den Boer (Wemos Foundation / HAI Europe)</td>
</tr>
<tr>
<td>15.40 - 16.00</td>
<td>MSF activities concerning medicines</td>
<td>Dr Doris Mesia (Médecins sans Frontières (MSF))</td>
</tr>
<tr>
<td>16.00 - 17.00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
## Day 2

### Filling knowledge Gaps for Priority Medicines for Children

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 09.20</td>
<td>Results from Institute for Paediatric Innovation (IPI) study in Tanzania</td>
<td>Dr Lisa Adams (Dartmouth’s Global Health Initiative)</td>
</tr>
<tr>
<td>09.20 - 09.40</td>
<td>Medicines for TB in children - update</td>
<td>Dr Anna Ridge, MAR</td>
</tr>
<tr>
<td>09.40 - 10.00</td>
<td>UK Medicines for Children Research Network and/or formulation work package of Global Research in Paediatrics (GRIP)</td>
<td>Professor Tony Nunn (Alder Hey Children’s Hospital, Liverpool, UK)</td>
</tr>
<tr>
<td>10.00 - 10.20</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>10.20 - 10.40</td>
<td>Estimating weight in children</td>
<td>Dr Susan Abdel-Rahman (The Children’s Mercy Hospital)</td>
</tr>
<tr>
<td>10.40 - 11.00</td>
<td>The National Institute of Child Health and Human Development (NICHD) Standards Initiative</td>
<td>Dr Steven Hirschfeld (NICHD)</td>
</tr>
<tr>
<td>11.00 - 11.20</td>
<td>Priority Essential Medicines for Children</td>
<td>Dr Sue Hill, MAR</td>
</tr>
<tr>
<td>11.20 - 12.30</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.30 - 13.30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

**Promote research and development of essential medicines for children by providing evidence, guidance, and specification**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30 - 13.50</td>
<td>Update of the implementation of the Paediatric Regulation</td>
<td>Dr Agnes Saint Raymond European Medicines Agency (EMA)</td>
</tr>
<tr>
<td>13.50 - 14.10</td>
<td>Medicines for Malaria Venture’s (MMV) work examining issues of national policy acceptance of paediatric medicines</td>
<td>Mr George Jagoe Medicines for Malaria Venture (MMV)</td>
</tr>
<tr>
<td>14.10 - 14.20</td>
<td>The International Paediatric Association (IPA) and International Union of Pharmacology (IUPHAR) activities</td>
<td>Dr Kalle Hoppu IPA and IUPHAR</td>
</tr>
<tr>
<td>14.45 - 15.15</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>15.15 - 16.15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16.15 - 16.30</td>
<td>Identification of needs and gaps</td>
<td>all</td>
</tr>
<tr>
<td>16.30 - 17.00</td>
<td>Wrap up &amp; next steps</td>
<td>Dr Clive Ondari / Dr Sue Hill</td>
</tr>
</tbody>
</table>
List of participants

PARTNERS

ALDER HEY CHILDREN’S NHS FOUNDATION
University of Liverpool
Eaton Road, GB-Liverpool L12 2AP

BILL & MELINDA GATES FOUNDATION
1551 Eastlake Ave. E
Seattle, WA 98102, USA

CARITAS INTERNATIONALIS
1, rue de Varembé
1202 Geneva 20, Switzerland

THE CHILDREN’S MERCY HOSPITALS AND CLINICS
Kansas City, USA

THE CLINTON HEALTH ACCESS INITIATIVE (CHAI)
383 Dorchester Ave., Boston, MA 02127
USA

DARTMOUTH COLLEGE
Hanover, NH 03755, USA

DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI)
15 Chemin Louis Dunant
1202 Geneva - Switzerland

ECUMENICAL ADVOCACY ALLIANCE
150 route de Ferney, P. O. Box 2100
CH-1211 Geneva 2
Switzerland

ECUMENICAL PHARMACEUTICAL NETWORK (EPN)

EUROPEAN MEDICINES AGENCY (EMA)
7 Westferry Circus
Canary Wharf London E14 4HB
United Kingdom

THE GLOBAL FUND
To Fight AIDS, Tuberculosis and Malaria
Chemin de Blandonnet 8
1214 Vernier, Geneva, Switzerland

REPRESENTATIVE

Professor Tony Nunn
Clinical Director of Pharmacy and
Associate Director, Medicines for Children
Research Network

Dr Saul S. Morris
Senior Programme Officer, Child Health
Integrated Health Solution Development

Ms Francesca Merico
International Delegate

Dr Susan Abdel-Rahman
Director, Development Pharmacokinetic and
Pharmacodynamic Core Laboratory

Ms Joanna Sickler
Paediatric Indication Manager
Clinton Health Access Initiative

Dr Lisa Adams
Assistant Professor
Infectious Diseases & International Health
Dartmouth Medical School

Dr Graciela Diap
Medical Coordinator - FACT Project

Ms Ruth Foley
HIV and AIDS Campaign Officer

Dr Albert Petersen
Pharmaceutical Aid Department
Difām, German Institute for Medical Mission
Paul-Lechler-Street 24
D-72076 Tübingen

Dr Agnes Saint Raymond
Head of Human Medicines Special Areas

Ms Carmen Pérez Casas
Senior Technical Officer
Global Health Supply
Pharmaceutical Management Unit
OXFAM
77 Lee Road, Blackheath
GB-London SE3 9EN

Mrs Philippa Saunders

PURDUE UNIVERSITY
3495 Kent Avenue
Ross Suite Q
West Lafayette, Indiana 47907, USA

Dr Daniel T. Smith
Department of Industrial and Physical Pharmacy

SAVE THE CHILDREN FUND
54 Wilton Road, Westport, CT 06880
USA

Dr Charles Ocan
Specialist, Africa Area Child Health and Nutrition
Save the Children Uganda
Plot 68/70 Kira Road, P.O. Box 12018
Kampala, Uganda

Ms Atieno Ojoo
Technical Specialist, Pharmaceuticals

UNICEF Supply Division
Unicef Plads, Freeport
2100 Copenhagen, Denmark

Dr Stuart MacLeod
Professor, Department of Paediatrics

UNIVERSITY OF BRITISH COLUMBIA
CHILD & FAMILY RESEARCH INSTITUTE
950 West 28th Avenue, Room A2-150
Vancouver, B.C. Canada V5Z 4H4

Mrs Elizabeth Finney
Chester NS, Canada

Ministry of Health (MoH):
MINISTRY OF HEALTH AND SOCIAL WELFARE
P. O. Box 9083, Dar es Salaam
Tanzania

Ms Anita Sillo (MoHSW, PSU, Pharmacist)

MINISTRY OF HEALTH
P. O. Box MB 582
Accra, Ghana

Mrs Martha Gyansa-Lutterodt
Programme Manager
Ghana National Drugs Programme

WHO Region/WRs:
WHO Regional Office for South-East Asia (SEARO)
World Health House
Mahatma Gandhi Marg
New Delhi - 110002, India

Dr Kathleen Holloway
Regional Adviser, Medicines

Office of WHO Representative - Tanzania
Luthuli Rd, opposite Karimjee Hall
P. O Box 9292, Dar es Salaam
Tanzania

Dr Gitanjali Batmanabane
Technical Officer - EDM

Office of WHO Representative - Ghana
29 Volta Street, Airport Residential Area
P. O. Box MB 142, Accra

Dr Rose Shija
National Programme Officer
Essential Medicines and Pharmaceutical Policies (EMP)

Office of WHO Representative - Ghana
29 Volta Street, Airport Residential Area
P. O. Box MB 142, Accra

Dr Mary Brantuo
National Programme Officer

Dr Edith Andrews Annan
National Programme Officer
**WHO headquarters:**
Health Systems and Services Cluster
Essential Medicines & Pharmaceutical Policies (EMP)
Medicine Access and Rational Use (MAR)

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coordinator, MAR</td>
<td>Dr Clive Ondari</td>
</tr>
<tr>
<td>MAR</td>
<td>Dr Suzanne Hill</td>
</tr>
<tr>
<td></td>
<td>Dr Krisantha Weerasuriya</td>
</tr>
<tr>
<td></td>
<td>Dr Hermann Garden</td>
</tr>
<tr>
<td></td>
<td>Dr Anna Ridge</td>
</tr>
<tr>
<td></td>
<td>Ms Alexandra Cameron</td>
</tr>
<tr>
<td></td>
<td>Ms Deirdre Dimanceso</td>
</tr>
<tr>
<td></td>
<td>Ms Barbara Milani</td>
</tr>
</tbody>
</table>

Family and Community Health Cluster
Child and Adolescent Health (FCH/CAH/CIS)

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAH/NCH</td>
<td>Dr Shamin Qazi</td>
</tr>
</tbody>
</table>